Early use of Biogen’s tofersen significantly slows disability progression, as well as a decline in lung function, muscle strength, and quality of life in amyotrophic lateral sclerosis (ALS) patients with mutations in the SOD1 gene, compared with a six-month delay in starting treatment. These benefits were accompanied by pronounced and sustained…
Starting Tofersen Early Slows ALS Progression Better: Trial Data
I’m all in when it comes to celebrating milestones, and as many of my readers know, I’m a glass-half-full person. So when June arrived, I didn’t have to look far for my first reason to celebrate. Happy 5 years to me! This month, I’m celebrating the five-year milestone of…
Dutch Bros Coffee has long supported efforts from the Muscular Dystrophy Association (MDA) to help patients with amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases and to fund research. It recently outdid itself, though, raising $2.3 million for the organization in a single day. Proceeds from Dutch…
Note: This story was updated June 7, 2022, to note that CENTAUR is a Phase 2, not Phase 2/3, trial and that AMX0035 reduced the risk of death by 43%, instead of 44%. There also has been no indication that U.S. sites will open soon for the PHOENIX trial.
Lisa Cross thought having amyotrophic lateral sclerosis (ALS) meant she would have to give up on acting and the theater. A longtime stage actor, Cross, 66, had worked in just about every aspect of the entertainment industry: she was a dancer and singer; a director, choreographer, and teacher; an…
Every Memorial Day, I go with my mom, daughter, and son to the Lakeside Cemetery in Hancock, Michigan, to attend a ceremony honoring veterans. I drive separately in case I need to return home quickly to help my husband, Todd, who has ALS. The ceremony ends with the…
Eledon Pharmaceuticals’ investigational antibody-based therapy, tegoprubart, safely and effectively reduces levels of inflammatory biomarkers in adults with amyotrophic lateral sclerosis (ALS), according to top-line data from a Phase 2a clinical trial. Exploratory findings suggested that lower levels of inflammatory biomarkers and whether tegoprubart’s target is significantly reduced,…
Major league baseball teams are poised to mark Lou Gehrig Day, set aside to honor the legendary New York Yankees first baseman whose career was cut short amyotrophic lateral sclerosis (ALS), the progressive neurodegenerative disorder that after his death in 1941 became known as “Lou Gehrig’s Disease.” In addition to…
Health Canada has started to review AB Science’s application requesting that masitinib be approved as an add-on therapy for amyotrophic lateral sclerosis (ALS). The application will be reviewed under the notice of compliance with conditions (NOC/c) policy, agreed upon with the agency in February. This policy allows early…
Stanley H. Appel, a world-renowned expert in amyotrophic lateral sclerosis (ALS) and the founder of the first multidisciplinary clinic dedicated to ALS care and research in the U.S., will receive the Tribute Award from the Muscular Dystrophy Association (MDA). The award acknowledges the neurologist’s work in pioneering ALS…
Recent Posts
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS
- Study probes high ALS risk in elite athletes and other ‘champions’
- First ALS patient dosed in study of experimental gene therapy VTx-002
- New collaboration targets protein buildup linked to brain diseases